JAGSONPAL PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 324.2 INR | -0.12% |
|
-5.60% | -16.62% |
| Mar. 08 | Jagsonpal Pharmaceuticals Limited Launches Queezy-ER® | CI |
| Feb. 02 | Jagsonpal Pharmaceuticals Limited Announces Chief Financial Officer Changes | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 2.26B 27.08M | Sales 2023 | 2.37B 28.35M | Capitalization | 7.59B 90.93M |
|---|---|---|---|---|---|
| Net income 2022 | 196M 2.35M | Net income 2023 | 267M 3.2M | EV / Sales 2022 | 3.42 x |
| Net cash position 2022 | 482M 5.77M | Net cash position 2023 | 1.09B 13.01M | EV / Sales 2023 | 2.75 x |
| P/E ratio 2022 |
41.9
x | P/E ratio 2023 |
28.4
x | Employees | 940 |
| Yield 2022 |
1.28% | Yield 2023 |
1.73% | Free-Float | 30.37% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.19% | ||
| 1 week | +0.32% | ||
| Current month | -9.14% | ||
| 1 month | +14.34% | ||
| 3 months | +2.82% | ||
| 6 months | -17.66% | ||
| Current year | -15.53% |
1 week
314.95
337.60
1 month
281.05374.00
Current year
273.60412.00
1 year
273.60514.85
3 years
93.35514.85
5 years
16.25514.85
10 years
12.60514.85
| Managers | Title | Age | Since |
|---|---|---|---|
Manish Gupta
CEO | Chief Executive Officer | - | 22-07-15 |
Abhishek Joshi
CMP | Compliance Officer | - | 23-02-12 |
| Director/Board Member | 67 | 78-08-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | 78-08-16 | |
Harsha Raghavan
CHM | Chairman | 52 | 22-06-28 |
Manish Gupta
CEO | Chief Executive Officer | - | 22-07-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 324.2 | -0.12% | 8 199 |
| 24-05-13 | 324.6 | +0.64% | 7,824 |
| 24-05-10 | 322.6 | -0.72% | 8,854 |
| 24-05-09 | 325 | -3.27% | 13,384 |
| 24-05-08 | 336 | +2.60% | 32,077 |
Delayed Quote NSE India S.E., May 14, 2024 at 04:24 am EDT
More quotes
Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its formulation products include Divatrone, Maintane 500 injection, Maintane 250 injection, Maintane Tablet, Indocap capsules, Metadec 50 injection, Metadec 25 injection, EndoReg Tablet, LycoRed softgels, LycoRed syrup, Doxypal DR-L Capsule, Yuliprist Tablet, COLLA-2 Tablet, Cystelia M, and DeeReg Tablet, among others. Its OTC products include Ringcuter Cream, Skin Lumia Soap-Antibacterial, and Skin Lumia Soap-Neem Tulsi. Its Naari products include Endoreg, Yuliprist, Verena, Kyrah, Krampoff, Endonorm EV2, Divagest SR 300, Divagest SR 200, Cystelia 35, Fibristone 25, and Cystelia-M. Its other products include Lycored Softgels, Lycored Syrup, JP Tone Syrup, and Doxypal DR-L. The Companyâs therapy areas include gynecology, orthopedics, and others.
Sector
Pharmaceuticals
Calendar
2024-05-27
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -15.53% | 103M | |
| +29.98% | 682B | |
| +31.74% | 586B | |
| -3.52% | 364B | |
| +18.59% | 327B | |
| +4.07% | 285B | |
| +16.38% | 240B | |
| +9.49% | 209B | |
| -8.75% | 203B | |
| +7.09% | 165B |
- Stock Market
- Equities
- JAGSNPHARM Stock